Core Insights - Scienture Holdings, Inc. has formalized multiple GPO agreements for Arbli, its FDA-approved losartan oral suspension, providing access to over 2500 healthcare institutions, which represents a potential penetration into approximately 20% of the U.S. institutional market [1][2][4] - The U.S. losartan market is valued at approximately $256 million annually, with 71 million prescriptions, indicating a significant opportunity for Arbli as the first ready-to-use oral suspension of losartan [1][3] Company Overview - Scienture Holdings, Inc. focuses on developing, commercializing, and distributing novel specialty pharmaceutical products that address unmet market needs [1][9] - The company aims to create long-term value for shareholders by expanding GPO partnerships and direct contracts to deepen institutional market penetration [2] Product Details - Arbli is a proprietary formulation of losartan, the first and only liquid formulation that does not require compounding, offering reduced dosing volume and a long shelf life at room temperature [2][4] - It is FDA-approved for treating hypertension in patients over six years old, reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients [5] Market Opportunity - The GPO agreements serve as a strategic gateway for rapid adoption of Arbli across member institutions, enhancing its market presence [4] - The liquid formulation of losartan addresses the risks and inconsistencies associated with compounded prescriptions, providing a safe and effective alternative for patients [2][4]
SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions